Board and Directors

The UK Dementia Research Institute (UK DRI) is governed by UK DRI Ltd (Company No. 11045257), which is established as a charitable company (Charity No. 1179589).


Board of Trustees

UK DRI is governed by a Board of Trustees, chaired by William Rucker.

The Board of Trustees meet quarterly and are responsible for the management of the institute’s activities.

UK-DRI-structure-copy.jpg#asset:3904


Scientific Strategy and Operational board

The 'Scientific Strategy and Operational board' is responsible for managing the delivery of the UK DRI’s scientific objectives. Membership includes the UK DRI Director, UK DRI COO and UK DRI Centre Directors, who meet monthly. We bring together multidisciplinary expertise in dementia research, in programmes of work shaped and delivered through the team of directors. Our leadership work collaboratively to form the scientific strategy of the institute, and ensure it meets its ambitious goals, reporting to the UK DRI Board of Trustees chaired by William Rucker.

Our Directors
  • Prof Bart De Strooper - UK DRI Director

    Prof Bart De Strooper (National director, based at UK DRI at UCL) is a world-renowned Alzheimer's disease researcher, formerly based at the KU Leuven in Belgium. He was Director at the Vlaams Instituut voor Biotechnologie and led a neuroscience department of over 250 researchers. Professor De Strooper’s research has focused on understanding the fundamental mechanisms that underlie Alzheimer’s and Parkinson’s disease. He is the recipient of several prestigious prizes in recognition of his work, such as the Brain Prize, the Potamkin prize, the Metlife Foundation Award for Medical Research and the Alois Alzheimer’s prize.

    Prof Bart De Strooper's Research Profile

    Bart De Strooper

  • Dr Adrian Ivinson - UK DRI Director, Operations

    Dr Adrian Ivinson (National director, based at UK DRI HQ at UCL) completed his undergraduate and graduate training in the UK before moving to the US where for eight years he was part of the Nature Publishing Group, including Editor of Nature Medicine and Publisher of the Nature monthly journals. He joined Harvard Medical School in 2001 as the founding Director of the Harvard NeuroDiscovery Center. After 12 years leading the centre, Dr Ivinson took the position of Director of Translational Research, allowing him to focus on those programmes with a more overt translational emphasis, and transitioned to Brigham and Women’s Hospital.

    Dr Adrian Ivinson's Profile

    Adrian Ivinson

  • Prof Karen Duff (UK DRI Hub at UCL)

    With over 15 years’ experience working in Alzheimer’s disease and currently Professor of Pathology and Cell Biology at Colombia University, we are privileged that Prof Karen Duff (Centre Director, UK DRI at UCL) will be returning to the UK in spring 2020 as Centre Director of the UK DRI’s hub in UCL. Completing a PhD in the Cambridge lab of Nobel Prize winner Sydney Brenner, Karen is now a leader in the field of neurodegenerative disease, having shared the prestigious Potamkin Prize in 2006. Her most notable work has been in the development of several transgenic research models, which have driven the field forward in its mission to find therapeutics for these devastating conditions.

    Prof Karen Duff's Research Profile

    Karen Duff

  • Prof David Rubinsztein (Interim - UK DRI at Cambridge)

    From a background in medicine, David Rubinsztein became Professor of Molecular Neurogenetics at the University of Cambridge in 2005. Obtaining his PhD from the University of Cape Town, he went on to lead the way in research of autophagy in neurodegenerative disease, with his lab discovering its role in intracytoplasmic aggregate-prone proteins. Author of more than 300 scientific papers, he has received numerous awards, including the Thudichum Medal (Biochemical Society) for outstanding contributions to neuroscience, the Roger de Spoelberch Prize, membership of EMBO, and fellowships of the Royal Society and the Academy of Medical Sciences. Prof Rubinsztein takes charge as Interim Centre Director of the UK DRI at Cambridge, following the departure of Prof Giovanna Mallucci in March 2022.

    Prof David Rubinsztein's Research Profile

    Prof David Rubinsztein

  • Prof Julie Williams (UK DRI at Cardiff)

    Professor of Neuropsychological Genetics at Cardiff University and Chief Scientific Adviser to the Welsh Government since 2013, Prof Julie Williams (Centre Director, UK DRI at Cardiff) is a world renowned expert in the genetics of Alzheimer’s disease. Having led global studies identifying new Alzheimer’s disease risk genes, her collaborative discovery of three such genes was recognised by TIME Magazine as one of the top ten medical breakthroughs of 2009. Julie is one of four leaders of the International Genomics of Alzheimer’s Project (IGAP) and Deputy Director for the MRC Dementias Platform UK (DPUK). She was awarded a CBE in 2012 for her contribution to Alzheimer’s research.

    Prof Julie Williams' Research Profile

    Julie Williams

  • Prof David Sharp (UK DRI Care Research & Technology based at Imperial and Surrey)

    With a background in traumatic brain injury, Prof David Sharp is in an expert in the use of advanced neuroimaging to study the human brain, with a particular focus on causes of cognitive problems across the brain network. After studying medicine at the Universities of Oxford and London, he obtained his PhD from the latter in 2006. David became an NIHR Professor at Imperial College London in 2012. He brings his expertise to the UK DRI Care Research & Technology Centre at based at Imperial and Surrey, where as Centre Director, he leads a ground-breaking research programme using technology to transform diagnosis and care for people living with dementia.

    Prof David Sharp's Research Profile

    David Sharp

  • Prof Giles Hardingham (UK DRI at Edinburgh)

    As Professor of Molecular Neurobiology at the University of Edinburgh, Giles Hardingham’s research looks into signalling between neurons and glia in the brain. His aim is to characterise the interactions that maintain brain homeostasis, and how these mechanisms break down in diseases that cause dementia. Having started his career at the University of Cambridge, Professor Hardingham worked at the MRC Laboratory of Molecular Biology before moving to Edinburgh, obtaining a Royal Society University Research Fellowship, and latterly a MRC Senior Non-Clinical Research Fellowship. Professor Hardingham is a former EMBO Young Investigator and Colworth Medal winner.

    Prof Giles Hardingham's Research Profile

    Giles Hardingham


  • Prof Paul Matthews (UK DRI at Imperial)

    Prof Paul Matthews (Centre Director, UK DRI at Imperial) is Head of the Division of Brain Sciences in the Department of Medicine at Imperial College London. He was the founding director of two internationally leading research imaging centres, the University of Oxford Centre for Functional Magnetic Imaging of the Brain and later, the GlaxoSmithKline Clinical Imaging Centre. As well as extensive academic experience, Professor Matthews served as Vice President of GlaxoSmithKline Medicines Discovery and Development between 2005 and 2014, and currently leads the imaging network for DPUK. His research aims to translate advances in brain imaging into clinical applications in neuroscience, including accelerating drug development. Professor Matthews was awarded an OBE in 2008 for services to neuroscience.

    Prof Paul Matthews' Research Profile

    Paul Matthews

  • Prof Jernej Ule (UK DRI at King's)

    Prof Jernej Ule has led the UK DRI at King’s as Centre Director since April 2022, and also holds the position of van Geest Professor of Neurodegeneration Research. Joining the UK DRI from a Group Leader position at the Francis Crick Institute, Prof Ule has over 20 years of experience in RNA biology research, and established his first group at the MRC Laboratory of Molecular Biology in Cambridge in 2006. His research is focused on a versatile molecule called ribonucleic acid (RNA), which has many roles in cells. For instance, messenger RNA carries the instructions to produce new proteins. RNA also interacts with proteins to form large complexes, and evidence suggests that changes in these interactions can lead to the characteristic toxic aggregates in neurodegenerative diseases such as ALS and Frontotemporal dementia. In his UK DRI programme, Prof Ule’s team aims to find out why this occurs and how to stop it using new therapeutics. In addition to his lab at the Crick, which is gradually being relocated to UK DRI at King’s, Prof Ule also leads a satellite research team at the Institute of Chemistry in Ljubljana, funded by the European Research Council.

    Prof Jernej Ule's Research Profile

    Jernej_Ule_1.jpg#asset:6391

HQ and Centre Scientific Advisory Boards

Each of our Centres have a Scientific Advisory Board (SAB) with prestigious members from across the globe. The SABs provide guidance and advice to our centres. We are grateful for their time and expertise.

Peer review feedback from SABs of each UK DRI Centre and from the UK DRI Institutional Advisory Boards complement our progress monitoring procedures. SABs provide annual feedback to each UK DRI Centre Director on the development and implementation of their Centre strategy and the progress of their research programmes, while the IAB will meet once a year to provide feedback to the UK DRI Directors on the strategic development of the UK DRI at national level.

UK DRI Scientific Advisory Boards

Founding funders

Latest tweets from @UKDRI

RT @ComplementUK: You don’t want to miss this exciting #workshop! Register 𝗯𝗲𝗳𝗼𝗿𝗲 summer holiday, by 25th 𝗔𝘂𝗴𝘂𝘀𝘁! 👉 https://t.co/iirkqVnbb
07 Jul 2022 15:23

RT @CharlotteLuff: I’ll be at #FENS2022 presenting a poster on the biophysics of temporal interference non-invasive deep brain stimulation.…
07 Jul 2022 12:39